Report Title:

Salvia Divinorum

 

Description:

Adds salvia divinorum and salvinorin A to list of Schedule I drugs

 


HOUSE OF REPRESENTATIVES

H.B. NO.

2179

TWENTY-FOURTH LEGISLATURE, 2008

 

STATE OF HAWAII

 

 

 

 

 

 

A BILL FOR AN ACT


 

 

relating to drugs.

 

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

 


     SECTION 1.  Chapter 329-14, Hawaii Revised Statutes, is amended to read as follows:

     "§329-14  Schedule I.  (a)  The controlled substances listed in this section are included in schedule I.

     (b)  Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

     (1)  Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

     (2)  Acetylmethadol;

     (3)  Allylprodine;

     (4)  Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);

     (5)  Alphameprodine;

     (6)  Alphamethadol;

     (7)  Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

     (8)  Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

     (9)  Benzethidine;

    (10)  Betacetylmethadol;

    (11)  Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide;

    (12)  Beta-hydroxy-3-methylfentanyl (N-[1-(2- hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);

    (13)  Betameprodine;

    (14)  Betamethadol;

    (15)  Betaprodine;

    (16)  Clonitazene;

    (17)  Dextromoramide;

    (18)  Diampromide;

    (19)  Diethylthiambutene;

    (20)  Difenoxin;

    (21)  Dimenoxadol;

    (22)  Dimepheptanol;

    (23)  Dimethylthiambutene;

    (24)  Dioxaphetyl butyrate;

    (25)  Dipipanone;

    (26)  Ethylmethylthiambutene;

    (27)  Etonitazene;

    (28)  Etoxeridine;

    (29)  Furethidine;

    (30)  Hydroxypethidine;

    (31)  Ketobemidone;

    (32)  Levomoramide;

    (33)  Levophenacylmorphan;

    (34)  3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);

    (35)  3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

    (36)  Morpheridine;

    (37)  MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

    (38)  Noracymethadol;

    (39)  Norlevorphanol;

    (40)  Normethadone;

    (41)  Norpipanone;

    (42)  Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide;

    (43)  PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;

    (44)  Phenadoxone;

    (45)  Phenampromide;

    (46)  Phenomorphan;

    (47)  Phenoperidine;

    (48)  Piritramide;

    (49)  Proheptazine;

    (50)  Properidine;

    (51)  Propiram;

    (52)  Racemoramide;

    (53)  Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);

    (54)  Tilidine;

    (55)  Trimeperidine;

    (56)  N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts, and salts of isomers; and

    (57)  N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts, and salts of isomers.

     (c)  Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1)  Acetorphine;

     (2)  Acetyldihydrocodeine;

     (3)  Benzylmorphine;

     (4)  Codeine methylbromide;

     (5)  Codeine-N-Oxide;

     (6)  Cyprenorphine;

     (7)  Desomorphine;

     (8)  Dihydromorphine;

     (9)  Drotebanol;

    (10)  Etorphine;

    (11)  Heroin;

    (12)  Hydromorphinol;

    (13)  Methyldesorphine;

    (14)  Methyldihydromorphine;

    (15)  Morphine methylbromide;

    (16)  Morphine methylsulfonate;

    (17)  Morphine-N-Oxide;

    (18)  Myrophine;

    (19)  Nicocodeine;

    (20)  Nicomorphine;

    (21)  Normorphine;

    (22)  Phoclodine;

    (23)  Thebacon.

     (d)  Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1)  Alpha-ethyltryptamine (AET);

     (2)  2,5-dimethoxy-4-ethylamphetamine (DOET);

     (3)  2,5-dimethoxyamphetamine (2,5-DMA);

     (4)  3,4-methylenedioxy amphetamine;

     (5)  3,4-methylenedioxymethamphetamine (MDMA);

     (6)  N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);

     (7)  3,4-methylenedioxy-N-ethylamphetamine (MDE);

     (8)  5-methoxy-3,4-methylenedioxy-amphetamine;

     (9)  4-bromo-2,5-dimethoxy-amphetamine(4-bromo-2,5-DMA);

    (10)  4-Bromo-2,5-dimethoxyphenethylamine (Nexus);

    (11)  3,4,5-trimethoxy amphetamine;

    (12)  Bufotenine;

    (13)  4-methoxyamphetamine (PMA);

    (14)  Diethyltryptamine;

    (15)  Dimethyltryptamine;

    (16)  4-methyl-2,5-dimethoxy-amphetamine;

    (17)  Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

    (18)  Ibogaine;

    (19)  Lysergic acid diethylamide;

    (20)  Marijuana;

    (21)  Parahexyl;

    (22)  Mescaline;

    (23)  Peyote;

    (24)  N-ethyl-3-piperidyl benzilate;

    (25)  N-methyl-3-piperidyl benzilate;

    (26)  Psilocybin;

    (27)  Psilocyn;

    (28)  1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);

    (29)  Tetrahydrocannabinols;

    (30)  Ethylamine analog of phencyclidine (PCE);

    (31)  Pyrrolidine analog of phencyclidine (PCPy, PHP);

    (32)  Thiophene analog of phencyclidine (TPCP; TCP);

    (33)  Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)-furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;

    (34)  1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;

    (35)  2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;

    (36)  N-benzylpiperazine (BZP; 1-benzylpiperazine) its optical isomers, salts, and salts of isomers;

    (37)  1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;

    (38)  Alpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers; [and]

    (39)  5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers;

    (40)  Salvia divinorum; and

    (41)  Salvinorin A.

     (e)  Unless specifically excepted, the schedule shall include any material, compound, mixture, or preparation which contains any quantity of the substance:

     (1)  Mecloqualone;

     (2)  Methaqualone.

     (f)  Stimulants.  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

     (1)  Aminorex;

     (2)  Cathinone;

     (3)  Fenethylline;

     (4)  Methcathinone;

     (5)  N-ethylamphetamine;

     (6)  4-methylaminorex;

     (7)  N,N-dimethylamphetamine."

     SECTION 2.  Statutory material to be repealed is bracketed and stricken.  New statutory material is underscored.

     SECTION 3.  This Act shall take effect upon its approval.

 

 

INTRODUCED BY:

_____________________________